Skip to search formSkip to main contentSkip to account menu

NSC-249992

Known as: NSC 249992, NSC249992 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Amsacrine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1983
1983
Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).
The clinical pharmacology of 4'-(9-acridinylamino)methanesulfon-m-anisidide (amsacrine) was studied, utilizing [9-14C]amsacrine i… 
1983
1983
A randomized phase II study of m‐AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non‐small cell broncliogenic carcinoma: An Eastern Cooperative Group Study
Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously… 
1982
1982
Comparative study of pulmonary fibrosis in Fischer 344 rats induced by bleomycin or pepleomycin
s (13) Pavkov, K . L ., D . C. Thake and C. R . Hassler: Toxicology of D-Amygdalin (NSC-15780) and D ,L Amygdalin (NSC-251222) in… 
1981
1981
Chemotherapeutic sensitivity of normal and leukemic hematopoietic progenitor cells to N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulfonamide, a new anticancer agent.
The sensitivities of hematopoietic colony-forming cells (CFC) to N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulfonamide (NSC… 
1981
1981
Evaluation of m-AMSA (NSC-249992) in the treatment of advanced head and neck cancer. Phase II study
1980
1980
m-AMSA: a new anticancer agent.
4'-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA; NSC-249992) is a new anticancer agent that has undergone extensive… 
1980
1980
Toxicology of m-amsa (nsc 249992) in beagle dogs and cdf1 mice. Abstr.
1980
1980
Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
Forty-one pediatric patients with advanced cancer (24 with acute leukemia and 17 with diverse solid tumors) received 74 courses… 
1979
1979
Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
4'-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA, NSC 249992), an acridine derivative, was given to 28 patients with solid… 
Highly Cited
1978
Highly Cited
1978
Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
The compound 4'-(9-acridinylamino)methanesulfon-m-anisidide is a new derivative that was evaluated in a Phase 1 clinical trial… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)